Aceso Life Science Group Ltd

Aceso Life Science Group Limited reported a net profit of HK$336 million for the year ended March 31, 2026, reversing a loss of HK$1,017 million in FY2025. Revenue from continuing operations, primarily rental income from its flagship UK property at 55 Mark Lane, rose to HK$58 million from HK$50 million a year earlier. The turnaround was supported by gains from the deemed disposal of its subsidiary Hao Tian International Construction Investment Group, while fair value losses on investment properties narrowed sharply to HK$17 million from HK$418 million. Financial assets at fair value through profit or loss recorded gains of HK$90 million versus losses of HK$25 million last year. Total assets fell to HK$1.79 billion from HK$3.24 billion, and the gearing ratio improved to 69.6% from 74.2% as borrowings reduced to HK$1.18 billion from HK$2.28 billion.